QUICK SNAPSHOT

Retatrutide

Weight Loss & Metabolic

FDA Status
Not FDA-Approved

Phase 3 TRIUMPH trials actively ongoing (2026)

Claimed Benefits
  • Obesity & weight loss (24.2% at 48 weeks)
  • Type 2 diabetes glycemic control
  • Fatty liver disease resolution
  • Appetite suppression
Clinical Evidence
5
Human Trials
Phase III
Highest Phase

12mg dose produced 24.2% mean body weight reduction at 48 weeks, among the highest ever recorded in a clinical obesity trial.

Read Full Deep Dive

Mechanism, dosing, vendor pricing, and full research citations

Monthly Digest

Stay ahead of the market

New peptide profiles, vendor pricing shifts, and research updates. No spam, unsubscribe anytime.